ImmuPharma plc (LON:IMM – Get Free Report) shares shot up 13% during trading on Wednesday . The stock traded as high as GBX 10.80 and last traded at GBX 10.47. 5,669,329 shares traded hands during trading, a decline of 30% from the average session volume of 8,065,854 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Price Performance
The firm’s 50-day simple moving average is GBX 11.19 and its 200 day simple moving average is GBX 5.50. The firm has a market capitalization of £51.28 million, a price-to-earnings ratio of -11.46 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Are These 3 Oversold Tech Giants Ready to Rebound?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- If You Wait for the Dip, Micron Technology Could Leave You Behind
- How to Use the MarketBeat Dividend Calculator
- 3 Stocks Quietly Powering the AI and Tech Revolution
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
